| The development of biopharmaceutical enterprises is closely related not only to people’s lives,but also to social stability and the development of productive forces.In the field of medical biopharmaceuticals,it involves capital intensive,integrates multiple industrial systems,and has a complex product listing process,increasing the potential for financial risks.With the acceleration of China’s medical and health system reform,the simultaneous promotion of the "trinity" new medical reform policy has created new strategic opportunities for the biopharmaceutical industry,but also brought great challenges.How to accurately identify the financial risks of enterprises and analyze and propose targeted preventive measures is the guarantee for the sustainable development of biopharmaceutical enterprises.Based on the relevant theories of financial risk and taking Z biopharmaceutical enterprises as the research object,this paper first selects 16 indicators from six aspects of financing risk,investment risk,operational risk,growth risk,and other risks in combination with the characteristics of the biopharmaceutical industry,and uses the entropy weight TOPSIS method to construct a financial risk evaluation system to identify the financial risks of Z enterprises,Through horizontal and vertical analysis,the risks of Company Z and listed companies in the same industry are ranked.The results show that Company Z has significant financial risks in recent years,ranking lower in the industry.Finally,based on the evaluation results,the risks existing in its daily production and operation investment are analyzed,and targeted prevention and control suggestions are proposed.The research in this paper hopes to help enterprises improve their risk control capabilities,promote their stable development,and provide some help and reference value for the development of the biomedical industry. |
PDF Full Text Request